Nat. Rev. Cardiol. doi: /nrcardio

Slides:

Advertisements

Similar presentations

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2009;5: A comparison of patient characteristics and 30-day mortality outcomes after.

Advertisements

Nat. Rev. Cardiol. doi: /nrcardio

Are we ready to perform TAVI in Intermediate Risk Patients?

From: Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve ReplacementA Systematic Review and Meta-analysis Ann Intern Med. 2016;165(5):

J. Matthew Brennan, MD, MPH Duke University School of Medicine

JAMA. 2014;312(2): doi: /jama Figure Legend:

Are we ready for expanding TAVI indications to moderate and low risk

A Meta-Analysis of Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement Hisato Takagi, MD, PhD, Masao Niwa, MD, Yusuke Mizuno,

From: Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve ReplacementA Systematic Review and Meta-analysis Ann Intern Med. 2016;165(5):

Nat. Rev. Cardiol. doi: /nrcardio

Hisato Takagi, MD, PhD, Takuya Umemoto, MD, PhD

Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement for Severe Aortic Stenosis in Patients With Chronic Kidney Disease Stages.

Nat. Rev. Cardiol. doi: /nrcardio

Transcatheter and Surgical Aortic Valve Replacement in Dialysis Patients: A Propensity- Matched Comparison Dale M. Kobrin, BA, Fenton H. McCarthy, MD,

Figure 5 TAVI with a self-expanding valve in

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Pathological specimens showing the most common reasons for bioprosthetic valve failure Figure 2 | Pathological specimens showing the most common.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Global rates of sodium, fruit, and vegetable intake

Figure 2 Size categorization of airborne pollutants

Reply The Annals of Thoracic Surgery

Median total new lesion volume

Figure 4 Valve-in-valve implantations in degenerated surgical valves

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Transcatheter or Surgical Aortic Valve Replacement in Patients With Prior Coronary Artery Bypass Grafting John V. Conte, MD, Thomas G. Gleason, MD, Jon.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Cardiovascular risk and disease across the life-course

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Decision tree integrating the assessment,

Aspects to be considered by the Heart Team for the decision between TAVR and SAVR in patients at increased surgical risk. Aspects to be considered by the.

Figure 4 TAVI for bicuspid aortic valve disease

Figure 1 Types of surgical and transcatheter aortic valves

Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: Changes in risks, valve types, and outcomes in the Society.

Figure 2 A patient with aortic stenosis and mitral regurgitation

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Gorav Ailawadi, MD, Damien J. LaPar, MD, MS, Alan M. Speir, MD, Ravi K

Suggested pathway for assessment of aortic valve replacement dysfunction. Suggested pathway for assessment of aortic valve replacement dysfunction. Transthoracic.

Nat. Rev. Cardiol. doi: /nrcardio

Raghavendra Paknikar, BS, Jeffrey Friedman, BS, David Cron, BS, G

Cost-effectiveness of the Edwards SAPIEN transcatheter heart valve compared with standard management and surgical aortic valve replacement in patients.

Sam Chitsaz, MD, Nicolas Jaussaud, MD, Edward Chau, MD, Kimberly S

Hisato Takagi, MD, PhD, Takuya Umemoto, MD, PhD

The risk and extent of neurologic events are equivalent for high-risk patients treated with transcatheter or surgical aortic valve replacement Thomas.

A Meta-Analysis of Minimally Invasive Versus Conventional Sternotomy for Aortic Valve Replacement Kevin Phan, BS(Adv), Ashleigh Xie, Marco Di Eusanio,

Transcatheter aortic valve replacement in intermediate-risk patients

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Box plot of hospital length of stay (in days) for the STD and TAVI groups before (blue) and after (green) the TAVI/turn-down date. Box plot of hospital.

Sutureless replacement versus transcatheter valve implantation in aortic valve stenosis: A propensity-matched analysis of 2 strategies in high-risk patients

N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels for patients undergoing surgical aortic valve replacement (SAVR) (A), patients undergoing.

Sung-Han Yoon et al. JACC 2017;69:

Deterministic univariate sensitivity analyses (BAV, balloon aortic valvuloplasty; ICU, intensive care unit; MM, medical management; QALY, quality-adjusted.

Racing to the Rubicon Michael J. Reardon, MD, Vinod H. Thourani, MD

Transcatheter aortic valve implantation versus surgical aortic valve replacement: A propensity score analysis in patients at high surgical risk Lenard.

NYHA before and after at least 30–60 days after TAVI

Nat. Rev. Cardiol. doi: /nrcardio

Presentation transcript:

Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.82 Figure 2 All-cause mortality in pivotal TAVI/SAVR studies grouped by risk category Figure 2 | All-cause mortality in pivotal TAVI/SAVR studies grouped by risk category. Cumulative all-cause mortality (%) over time is shown for the pivotal studies comparing transcatheter aortic valve implantation (TAVI) to medical therapy in inoperable patients and TAVI versus surgical aortic valve replacement (SAVR) for high, intermediate, and low-risk patients in various other cohorts. Mortality is represented at 30-days, 1-year, 2-years, and 5-years when available. The graph shows that as TAVI has been extended to lower risk cohorts, overall mortality has dropped considerably. *81.8% of patients are low risk, with a mean Society of Thoracic Surgeons score of 3.0% for the overall cohort. Jones, B. M. et al. (2017) Matching patients with the ever-expanding range of TAVI devices Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.82